Published: 13 July 2021
Author(s): Srikanth Yandrapalli, Rahul Gupta, Aaqib H. Malik
Issue: October 2021
Section: Letter to the Editor

Atrial fibrillation (AF) is commonly encountered in clinical practice by internists and specialists, both in the inpatient and ambulatory settings. AF increases the risk of stroke or systemic embolisation (SSE) and heightens the associated morbidity and mortality [1]. Warfarin and direct oral anticoagulants (DOACs) have shown benefit in reducing SSE events in patients with AF; however, studies that established the non-inferiority of DOACs compared with warfarin included patients with non-valvular atrial fibrillation (NVAF) [2–5].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.